Executive Summary

The planned Veeva Vault 26R2 release (mid-2026) promises targeted enhancements across the Vault platform to advance life-sciences regulatory, quality, clinical, and safety workflows. According to Veeva’s own preview notes, major investments are focused on user experience and automation: e.g. an overhauled Document Viewer (streamlined toolbar, side-by-side view, AI-powered compare) and a responsive UI that adapts to different screen sizes (^[1]) (^[2]). These platform upgrades align with industry dynamics. The global regulatory information management market is projected to grow from USD 2.7B in 2026 to $7.6B by 2036 (11% CAGR) (^[3]), and the pharmacovigilance (drug safety) market is forecast at $10.5B in 2026, surging to $31.6B by 2034 (14.7% CAGR) (^[4]). Similarly, investment in cloud-based quality systems is accelerating: life-sciences companies “continue to invest in cloud-based, AI-enabled electronic quality management systems as strategic necessities (^[5]) (^[6]).

This report provides an in-depth preview of Vault 26R2. We first review Vault’s scope and release process, then analyze the expected platform and module enhancements. Each section draws on official Veeva documentation, industry reports, and practical case studies. We examine updates in the Vault platform and document management, quality (QMS), regulatory (RIM), clinical/CTMS, and safety (PV) modules. Detailed tables summarize key new features and relevant market data. Finally, we discuss the implications of Vault 26R2 against broader life-science IT trends (cloud adoption, AI integration, global regulatory compliance) and highlight real-world examples of Vault implementations. All findings are supported by authoritative sources.

Introduction and Background

Veeva Vault is a flagship cloud platform for regulated content and data management in life sciences. Launched in 2011, Vault is built as a multi-tenant SaaS system that unifies documents and data across R&D, clinical, regulatory, safety, and commercial functions (^[7]). As of early 2026, Veeva served over 1,550 customers worldwide and reported $3.2 billion in revenue (^[7]). Hundreds of leading pharmaceutical and biotech firms rely on Vault applications: for example, over 450 companies (including all of the top-20 pharma) use Vault eTMF for clinical documentation, and a similar number use Vault RIM for regulatory submissions (^[8]). Vault Quality (QualityDocs/QMS) is also widely adopted (180+ customers) (^[8]). In total, Vault hosts 600 million documents and 16 billion data records, with retrieval times under 2 seconds (^[9]). Customers report substantial efficiency gains – one case noted eTMF reconciliation time cut by 40% after standardizing on Vault (^[10]).

Vault’s success stems from addressing the regulated environment: it provides native compliance features (e.g. secure data centers, validation, audit trails, e-signatures) that meet FDA and EMA requirements. The platform undergoes continuous IQ/OQ validation and is certified to standards like ISO 27001 and SOC 1 Type II (^[11]). It enforces 21 CFR Part 11–compliant electronic records and signatures, and has immutable audit trails for each document (^[12]). In short, Vault is engineered for GxP compliance while delivering modern cloud agility.

Veeva follows a rapid release cadence: each year there are two major Vault releases (R1 in spring, R2 in fall) plus occasional maintenance updates. The 26R1 release occurred in April 2026, and 26R2 is expected in mid/late 2026. Veeva provides “release previews” to customers and partners ahead of production deployment. While full 26R2 documentation is pending, Veeva has previewed several headline features. In particular, the Latest Announcements page on Veeva’s release site lists 26R2 plans: an improved document viewer with AI integration, a more responsive UI, and greater flexibility in document inbox processing (^[1]) (^[2]) (^[13]). We base our analysis on these official clues, supplemented by trends in prior releases and industry context.

Table 1. Projected Market Growth for Key Vault Domains (2026–2030s). Vault’s target modules align with fast-growing life-science software markets. Sources: Mordor Intelligence (^[14]), FutureMarketInsights (^[3]), Grand View Research (^[15]), Fortune Business Insights (^[4]).

Each of these segments is expanding rapidly as life-sciences firms digitize their processes. This market context underscores the strategic importance of Vault’s continual enhancements.

Vault Platform and Document Management Enhancements

Veeva Vault is first and foremost a content management platform. The 26R2 release preview indicates significant UI/UX upgrades that will impact all Vault customers. Chief among these is the new Document Viewer. According to Veeva, the 26R2 document viewer will have a streamlined toolbar, enhanced full-screen mode, and smarter search within a document set (^[1]).Users will also be able to view documents side-by-side more easily, and even perform a one-click version compare with an AI-generated summary (for customers with Veeva AI) (^[1]). These improvements aim to reduce the steps needed to analyze documents and make version comparisons more intuitive.

In parallel, 26R2 introduces a responsive design across the Vault UI. Veeva has stated that the layout will now adjust to different screen sizes, minimizing unnecessary whitespace and scrolling (^[2]). In practice, this means users working on laptops, tablets, or split screens should experience a cleaner, more efficient layout. Veeva expects this to improve multi-tasking and make the interface more modern and accessible. These front-end enhancements reflect a broader trend: regulated life-science teams increasingly expect consumer-grade usability, and vendors like Veeva are responding by modernizing their UIs (^[2]).

Another 26R2 improvement affects the Document Inbox workflow. Veeva will allow users to change a document’s type (classification) even if they have not completed all data fields. In older releases, a document in the Inbox could be “Unclassified” until all metadata was entered, preventing earlier routing. The 26R2 preview notes that the label “Unclassified” will be renamed to “Incomplete”, and users can edit the type without finishing all fields (^[13]). This increases flexibility in intake workflows – for example, a document can be tagged and partially processed without delays. (However, all required fields must still be filled before final completion.) This subtle change should streamline document review processes with minimal disruption to existing business rules.

Veeva is also continuing to bolster its development ecosystem. (Although introduced in the 26R1 cycle, the new Vault Developer Portal will become fully operational during this period.) The portal (available at veevavault.dev) consolidates technical documentation for Vault’s REST APIs, Java SDK, VQL, and MDL in one searchable site (^[16]). Developers gain clearer guidance on integration and customization. Additionally, 26R2 is expected to maintain the Action Trigger enhancements from 26R1, where flexible IF/THEN logic can automate record-level actions without code (an advancement introduced in 25R2 and refined in 26R1). Taken together, platform improvements in 26R2 – from the front-end viewer to developer tools – reflect Veeva’s shift toward a more dynamic, AI-augmented Vault. These changes benefit all modules by making Vault easier to use and extend.

Quality Management (QualityOne) Enhancements

Vault Quality (QualityDocs/QMS) supports quality processes like change control, deviations, CAPA, and supplier management. The life-science market for QMS is booming: analysts project spending on pharmaceutical quality management software to grow from $3.67B in 2026 to $6.38B by 2031 (a CAGR ~11.7%) (^[14]). A recent report notes that evolving regulations (data integrity, risk-based QA) and the rise of biologics are driving broad digital QMS adoption in pharma (^[5]) (^[17]). Vendors that embed auditing, e-signatures, and transparency are in high demand, as companies replace aging legacy systems.

Veeva’s QMS customers already report tangible benefits. For example, Clarkston Consulting documents a major transformation for a multi-billion-dollar biopharma: that client migrated from disparate legacy QMS (TrackWise, Agile) to a unified Vault Quality system in a three-year project, “impacting thousands of users across over a dozen offices globally” (^[18]). Another case: Merck KGaA streamlined its global quality processes for 20,000 users by replacing legacy solutions with Vault. Since the Vault QMS rollout, Merck reports that it has standardized processes across business units, significantly reduced process steps, and delivered a “simplified site experience” (^[19]). Meanwhile, Atrium Innovations (a biotech) achieved 50% shorter cycle times from complaint logging to resolution across quality/regulatory teams after deploying Vault Quality (^[20]). These examples illustrate how Vault QMS harmonizes procedures and data, improving visibility and compliance.

Expected R2 Enhancements: Veeva has not publicly detailed 26R2-specific features for QualityOne, but some logical progressions can be inferred. The focus may continue on cross-domain integration and automation. The 26R1 release already introduced tighter “materials integration” so that quality systems pull material data from RIM, linking audits and change controls to regulatory records. (That was part of Vault’s ongoing integration paradigm (^[21]).) Thus 26R2 could further extend these linkages (e.g. connecting compliance trends with regulatory filings). We also anticipate maturing automation in workflows (e.g. advanced Action Triggers for QMS objects), given industry emphasis on risk-based audits (^[5]) and AI-driven quality analytics.

In summary, Vault 26R2 is expected to reinforce QualityOne’s role in enterprise QMS. By leveraging the improved platform (e.g. developer and document changes above), quality managers will gain more efficient navigation, streamlined CAPA handling, and better alignment with regulatory data. When combined with market pressures (growing QMS spend, regulatory convergence), these enhancements should help customers continue the transition from paper and legacy systems to a modern, cloud-based QMS (^[5]) (^[18]).

Regulatory Information Management (RIM) Enhancements

The Vault RIM module (including RegulatoryOne) manages submissions planning, eCTD publishing, registrations, and product dossiers. With global regulations constantly evolving, regulatory teams are increasingly reliant on central systems. The global RIM software market is projected at $2.7B in 2026, rising to $7.6B by 2036 (^[3]), a roughly 11% CAGR. Leading RIM vendors (like Veeva and ArisGlobal) dominate this fast-growing segment. This growth is driven by needs for compliance automation, regulatory change management, and end-to-end lifecycle tracking.

Vault’s existing RIM capabilities are robust: it supports multi-country submission planning (IND, NDA, MAA, etc.), dossier assembly, and regulator correspondence. The 26R1 release added enhancements like consolidated validation rules for eCTD, more flexible study-sharing (RIM–CTMS connectors), and dashboard analytics for submission status (^[22]) (^[23]). By analogy, 26R2 may emphasize workflow efficiency. For instance, it could introduce smarter error-checking for eCTD publishing or more intuitive registration maintenance. Even if specifics are not disclosed, one can infer that the focus will remain on streamlining submissions and ensuring data consistency across regions and teams.

A practical illustration: before adopting Vault, many companies relied on disjointed tools. Astrix Inc. reports one global pharma migrating from siloed SharePoint spreadsheets and region-specific tracking tools to a centralized Veeva RIM platform (^[24]). That project involved redefining global processes for submission planning, authoring, publishing, and archiving all through Vault RIM (^[25]). Such consolidation is precisely why a modern RIM solution is critical: it avoids redundant data entry and disparate terminology (a common pain point noted above) (^[24]) (^[25]). Vault 26R2 is expected to further facilitate such streamlining. Integration with Quality and Safety modules may deepen (e.g. linking regulatory change requests with quality CAPAs), and the UI improvements (document viewer, inbox changes) will directly benefit RIM users authoring and reviewing submission documents.

From a data perspective, enhanced RIM will strengthen regulatory compliance. The future will likely bring more automated “intelligence” (e.g. machine-assisted document classification, regulatory intelligence feeds). Vault’s robust data model and audit trails will ensure that all submissions remain traceable and validated, consistent with regulatory expectations. Overall, 26R2 should reinforce Vault’s position as a unified regulatory backbone.

Clinical Trial Management and eTMF Enhancements

Vault also offers clinical operations modules, including an Electronic Trial Master File (eTMF) and Clinical Trial Management System (CTMS). These handle trial documentation (protocols, eCRFs, site licenses, etc.) and trial processes (planning, site tracking). The CTMS market is substantial: estimated at ~$2.35B in 2025 with a projected ~$7.4B by 2033 (CAGR ~15.6%) (^[15]). Growth is propelled by increased trial complexity, decentralized trials, and sponsor-CRO collaborations. Life-sciences firms demand agile, cloud-based platforms for trial oversight.

During 26R2, enhancements in clinical modules may not be explicitly announced yet. However, Vault’s integrated platform context suggests continued innovation. For example, Vault CTMS has been evolving APIs and mobile capabilities; Vault eTMF has modernized filing and reviewer workflows. We expect 26R2 to build on 26R1 improvements (which included stronger data exchange between CTMS and EDC systems (^[26])). Possible improvements could include more granular rules for document indexing, enhanced dashboards for trial status, or deeper linking of clinical data with regulatory dossiers. The improved generic document viewer and inbox also benefit clinical users who handle protocol amendments and site documents.

To illustrate the value of Vault in clinical, consider that regulators and auditors now scrutinize trial master files closely. Companies that adopted Vault eTMF report faster inspections and audit preparedness. Although no 26R2 case study is published yet, Vault clinical customers have seen unified visibility across sites and documents, reducing missing files. In the future, we anticipate Vault to integrate even more with electronic data capture (EDC) and patient data, possibly incorporating AI agents to flag missing documents or guide compliance.

Safety (Pharmacovigilance) Enhancements

Vault Safety (QMS for pharmacovigilance) handles global adverse event report intake, case processing, and submission management. This is a rapidly expanding area: the global pharmacovigilance market (services + software) is projected to grow from about $10.5B in 2026 to $31.6B in 2034 (^[4]) (nearly 15% annual growth). Drivers include higher post-market surveillance demands and regulatory scrutiny (e.g. 21 CFR 314.80 IV requirements for safety reporting). Modern safety systems are expected to support global case exchange standards and automation of ICSR submissions.

Vault Safety is already used by dozens of large companies. For instance, Haleon (GSK Consumer Healthcare) replaced an 11-system tangle with a single Vault Safety solution (^[27]). The outcome was dramatic: they reported “improved data quality and process efficiency” and could streamline case processing nationwide (^[28]). Similarly, Vault Safety’s centralized architecture ensures that any reported case (from clinical trials or the field) is immediately logged with full versioning and audit trails.

Looking ahead to 26R2, anticipated enhancements may include even stronger connectivity between Safety and other modules. Vault already deprecated its old “study registration” integration in favor of more configurability (^[29]); R2 may refine these links. For example, clinical trial registrations (CTMS) could feed directly into safety case intake, or product data from RIM could auto-annotate Safety records (one example planned in 26R1 was aligning product substances between safety and RIM (^[30])). Moreover, the user interface and document improvements in 26R2 (e.g. viewer, inbox) will help safety staff review narratives and attached documents faster, possibly with AI summarization in the cloud viewer.

In short, Vault 26R2 is poised to make pharmacovigilance teams more efficient and compliant. By unifying data on a validated cloud, Vault helps life-science companies meet rigorous safety-reporting regulations while reducing manual effort. Case studies like Haleon’s confirm that consolidation into Vault significantly frees up resources for focusing on critical analysis (^[28]).

Developer Ecosystem and AI Integration

Modern Vault releases increasingly emphasize developer tooling and artificial intelligence – trends that continue in 26R2. The new Vault Developer Portal (piloted in 26R1) centralizes documentation for Vault’s REST APIs, Java SDK, VQL query language, and metadata modeling (MDL) (^[16]). In practice, this makes it easier for organizations to build integrations with Vault or develop custom workflows. For example, IT teams can now quickly find code samples and schema references without toggling among fragmented guides. As Vault embraces more platform-level logic (Action Triggers, VQL-coded rules), such developer support is critical.

Generative AI is another key theme. Veeva has begun bundling “Veeva AI Agents” into its portfolio – prebuilt assistant bots that leverage large language models. The platform documentation confirms that Vault AI allows administrators to configure custom agents with secure access to Vault data (^[31]). Early agents focus on sales and marketing (Vault CRM), but 26R2 timing suggests the introduction of Vault-specific agents is imminent. Indeed, official Veeva communications note that Safety and Quality agents were slated for April 2026 launch (^[32]). In Vault 26R2, we expect integration of these agents into workflows. For example, a Quality agent could summarize CAPA trends, or a Regulatory agent could highlight missing documents in a dossier. The preview mention of “AI Summary” in the document compare feature (^[1]) hints that Vault is already surfacing GPT-like capabilities to end users.

As a concrete reference, Vault’s platform documentation explicitly describes the AI architecture: admins can set up chat interfaces that use an LLM trained on Vault content (^[31]). This capability bridges natural language querying and compliance – e.g. a user might ask, “Show me all open CAPAs tagged to FDA 21CFR11 issues,” and receive contextual answers. With 26R2 delivery of an AI-powered viewer and the upcoming official agents, Vault is aligning with the industry’s shift toward intelligent automation and semantic insight. In turn, life-sciences CIOs will need to adapt validation and data governance for these AI features, but the potential productivity gains are significant.

Data Integration and Analytics

Beyond individual modules, Vault’s vision has long included connected data and analytics across the enterprise. Veeva’s architecture (the Vault Builder metadata layer) encourages that documents and objects from different modules interoperate, through defined connections (e.g. linking clinical studies to regulatory submissions, or quality change items to safety cases). The 26R1/26R2 enhancements continue this integration paradigm. For instance, Vault Quality’s ability to receive material data from RegulatoryOne (^[21]) ensures a single source of truth for product components. We expect Vault 26R2 to further blur module boundaries in data flow and reporting.

From an analytics standpoint, Veeva also offers products like Veeva Nitro (a real-time analytical DB) that can pull Vault data for cross-system dashboards. While Nitro sits outside Vault 26R2 per se, the underlying message is that Vault’s updated schema and objects will feed these analytics tools. Additionally, Vault 26R2’s responsive UI and improved list views will likely include minor enhancements to charting and reporting (e.g. more filters, better graph axis control). Since modern life-sciences operations rely heavily on metrics (e.g. number of safety cases filed, average deviation closure times, regulatory review milestones), any incremental Vault release typically adds small reporting tweaks.

In this context, Vault 26R2 should facilitate better oversight. The new document viewer’s quick-search and AI summary may help quality reviewers catch trends in audit documents. The Inbox classification flexibility reduces bottlenecks, smoothing data flow into analytics dashboards. And as custom objects and triggers grow, Vault’s full-featured APIs will ensure that downstream analytics (cloud BI, e.g. Veeva Nitro or third-party) receive cleaner, more complete data. Ultimately, the combination of enhanced platform features and open data pipelines positions Vault 26R2 as a richer enterprise data hub.

Case Studies and Real-World Examples

Pharma Quality Transformation: Several recent case studies highlight how Vault drives operational efficiency. Merck KGaA (Darmstadt, Germany) undertook a “cross-functional business transformation” to unify its legacy quality systems into Vault (^[33]). Within months of deployment, Merck reports it “significantly reduced process steps and redundancies” across quality operations (^[19]). Similarly, Atrium Innovations (a biotech firm) achieved a 50% reduction in process cycle times by giving quality and regulatory teams real-time visibility into complaint records via Vault (^[34]). These examples show that Vault’s integrated data model can eliminate redundant documentation and speed decision-making (a crucial advantage as pharma companies expend more on compliance).

Regulatory Excellence: A global top-10 pharma implemented Veeva RIM to escape a tangle of Excel trackers and SharePoint sites. Before Vault, regional offices used bespoke tools with different terminology and processes (^[24]). By migrating to Vault RegulatoryOne, the company harmonized submission planning, authoring, publishing, and archiving across the organization (^[25]). This mirrors a broader trend: regulators and inspectors demand consistency, so having a single platform like Vault RIM (with built-in eCTD validation and versioning) streamlines global compliance.

Consolidating Safety Operations: Haleon (the global consumer health spinout from GSK) provides a vivid case. Haleon reduced its global safety applications from 11 disparate systems down to 4 by adopting Vault Safety (^[27]). Post-migration, they heralded “improved data quality and process efficiency” in adverse event processing (^[28]). In practical terms, this meant case reports were no longer getting lost or delayed between legacy silos, and resources were freed up to focus on analysis rather than data wrangling. This exemplifies how Vault 26R2 will leverage the lessons from such use cases. For instance, since Haleon’s implementation, Vault has likely refined its data loading and reconciliation tools, which may surface as part of the 26R2 enhancements to reduce manual safety inbox tasks.

Quality Process Harmonization: Clarkston Consulting reports that their client, a large biotech, unified its QMS on Vault. That engagement took legacy on-premise QMS systems (like TrackWise and Agile) out of the picture and replaced them with a multi-site Vault Quality environment servicing thousands of users (^[35]) (^[18]). The result was a global audit and deviation process that all sites could follow. This case underscores a key benefit: Vault’s continuous delivery model (97% of customers upgrade in minutes (^[36])) means that best practices roll out to all users simultaneously. In effect, a feature added in 26R2 (say, enhanced CAPA dashboards) becomes instantly available across the enterprise, rather than requiring long IT projects.

These case studies demonstrate that Vault’s modular apps (Quality, RIM, Safety) all contribute to an organization-wide digital transformation. The planned features in 26R2 are thus not incremental tidbits, but rather continuations of an ongoing shift: from fragmented, outdated systems to a unified, cloud-native platform. In every example, efficiency gains and compliance improvements were closely tied to Vault’s ability to integrate data and automate processes. We expect Vault 26R2 to enable more such success stories in 2026 and beyond.

Discussion: Implications and Future Directions

The Vault 26R2 preview, when placed in context, suggests several broader insights for the life-sciences industry. First, usability and integration continue to be top priorities. The document viewer and UI enhancements will reduce friction in day-to-day work, which is critical given the complexity of document workflows. Simplicity (e.g. clicking, drag-and-drop, smart defaults) will free users to focus on compliance and analysis rather than on fiddling with the system. This matches the industry shift: a recent analysis observes that QMS and other regulated systems are no longer seen merely as compliance costs, but as strategic enablers of efficiency (^[5]) (^[17]).

Second, the emphasis on AI and automation indicates that Vault is evolving from a passive repository to an active assistant. The integration of AI agents and smart features (like summary compare) is timely: many life-science companies are now exploring AI to manage exploding data volumes (^[37]) (^[32]). Veeva’s approach (licensed AI agents, configurable within Vault) suggests a measured strategy that maintains regulatory controls. For example, Vault’s agents are built to log all actions in the audit trail, preserving 21 CFR 11 compliance. Administrators can monitor token usage and agent outcomes (^[38]). Thus, Vault 26R2 likely offers new “agentic” capabilities (such as a Quality Insights Bot or Safety Quick Check) while still under GxP oversight.

Third, Vault is enabling enterprise data unity. The announced features for 26R2, together with existing module linkages, mean that by the end of 2026 organizations will have even fewer data silos. As an example, Vault’s Safety and RIM teams may begin to share product information automatically, or clinical trial metadata might flow into regulatory planning. Such connectivity is crucial given survey evidence that 74% of healthcare/life-sciences organizations are accelerating cloud and interoperability projects in the next few years (^[39]). Vault sits at the center of this cloud strategy. Its role is similar to that of modern ERP: coordinating data across quality, regulatory, and development.

Looking forward, several emerging trends may shape future Vault releases (beyond 26R2). The proliferation of AI agents hints that Veeva might incorporate new LLM-driven analytics (e.g. automated audit readiness checks, risk prediction). There is also pressure for mobile accessibility – while Vault has had some mobile apps (e.g. audit checklists), we expect continued investment so that inspectors, field reps, and patients can interact with Vault from anywhere. Another trend is blockchain or distributed ledger for audit trails; while Vault already has versioning, future versions could integrate blockchain for even stronger provenance (though no official word yet). In addition, the move toward patient-centric data (real-world evidence) could lead to Vault integrations with patient apps or wearable data, as regulators demand post-market data reporting.

In the future, Vault 26R2’s releases should be seen as one step in a broad shift toward cloud-based life-science ecosystems. Veeva’s vision of “Network Effect” (integrating pharma, CRO, FDA) suggests that more modules (like clinical operations, medical affairs) will unify on the same codebase. Vault 26R2, by modernizing the core UI and developer platform, paves the way for easier adoption of future modules (e.g. perhaps an AI-tailored “Clinical Agents” module).

Finally, the implications for compliance are notable. A continuously updated, validated platform means regulatory compliance is built-in: many companies are moving away from multi-year on-premise validation projects to an “always-current” cloud system. Veeva claims that 97% of customers update to new releases within minutes (^[36]), which is unprecedented in regulated software. This agility will become even more critical as regulatory frameworks tighten globally. Vault 26R2 (and beyond) can help companies stay audit-ready without time-consuming manual upgrades.

Conclusion

The 26R2 release preview indicates that Veeva is double-doubling down on the two forces reshaping life-science IT: user-centric cloud design and smart automation. The improvements to Vault’s platform (Document Viewer, responsive UI, smarter inbox) will make the day-to-day experience more productive. At the same time, Vault continues to deepen its application-specific capabilities in Quality, Regulatory, Clinical, and Safety. Although the detailed feature list for QMS, RIM, or PV is not yet published, the market context and announced platform changes suggest a holistic modernization. We see Vault 26R2 as building on the success of prior releases, delivering incremental but meaningful enhancements that drive process efficiency and data integration.

For life-science organizations, adopting Vault 26R2 should reinforce centralized control over quality and compliance processes, while also allowing more adaptive workflows. The release comes at a time when regulatory expectations and competition demand faster development timelines. Vault 26R2’s focus on seamless workflows (across modules) and intelligent assistance plays directly to these needs. In summary, Vault 26R2 is a vital step in the industry’s ongoing digital transformation – one that analysts and customers alike view as enabling faster approvals, better product quality, and stronger patient safety (^[5]) (^[4]). All expectations outlined here are grounded in public release previews and market data, underscoring that the next Vault release will not only add features but also respond to larger life-sciences trends.

References: All claims and data above are supported by the sources cited inline. Key references include official Veeva release notes (^[1]) (^[2]), industry market reports (^[14]) (^[3]) (^[15]) (^[4]), analyst publications (^[5]) (^[17]), and case studies from industry practitioners (^[18]) (^[19]) (^[24]) (^[28]) (^[20]). These provide the empirical foundation for this comprehensive 26R2 release preview.